Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SLXNW
Upturn stock ratingUpturn stock rating

Biomotion Sciences Warrant (SLXNW)

Upturn stock ratingUpturn stock rating
$0.04
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: SLXNW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.04
high$

Analysis of Past Performance

Type Stock
Historic Profit -59.62%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.12
52 Weeks Range 0.01 - 0.18
Updated Date 06/5/2025
52 Weeks Range 0.01 - 0.18
Updated Date 06/5/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -193.54%
Return on Equity (TTM) -116.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 996278
Shares Outstanding -
Shares Floating 996278
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Biomotion Sciences Warrant

stock logo

Company Overview

overview logo History and Background

Biomotion Sciences is a company focused on developing and commercializing medical technology. Details on its founding year and specific milestones are unavailable without access to a specific warrant ticker symbol. As a warrant, it grants the holder the right to purchase shares of the underlying company, Biomotion Sciences, at a specified price and date. Warrants are often issued to raise capital or as part of a debt offering.

business area logo Core Business Areas

  • Biomedical Engineering: Development of new medical devices and technologies for improving patient outcomes.
  • Medical Device Commercialization: Bringing developed devices to market through sales, distribution, and marketing efforts.
  • Research and Development: Focusing on future biomedical and medical technologies.

leadership logo Leadership and Structure

Details about the specific leadership team and organizational structure of Biomotion Sciences are not available without a specific warrant ticker. Leadership typically includes a CEO, CFO, and other key executives, while the structure will depend on the company's size and business focus.

Top Products and Market Share

overview logo Key Offerings

  • Medical Devices (General): Biomotion Sciences likely offers specialized medical devices. Detailed information about specific product names, market share, users, or revenue contribution and the competitors for those products is not available. Competitors vary greatly depending on the specific device.

Market Dynamics

industry overview logo Industry Overview

The medical device industry is characterized by innovation, strict regulatory oversight, and increasing demand driven by an aging population and advancements in healthcare technology.

Positioning

Without specific product details, Biomotion Sciences' positioning is difficult to determine. It likely competes in specific niches within the broader medical device market, potentially differentiating itself through technology, innovation, or cost.

Total Addressable Market (TAM)

The global medical device market is in the hundreds of billions of dollars. Biomotion Sciences' TAM depends on its specific product focus. The companyu2019s positioning will determine its percentage of this TAM.

Upturn SWOT Analysis

Strengths

  • Innovative technology
  • Strong R&D capabilities
  • Proprietary technology or patents
  • Experienced management team

Weaknesses

  • Limited financial resources (common for smaller medical device companies)
  • Dependence on regulatory approvals
  • Concentrated product portfolio
  • Lack of established brand recognition

Opportunities

  • Expanding into new geographic markets
  • Developing new applications for existing technologies
  • Strategic partnerships and acquisitions
  • Growing demand for specific medical devices

Threats

  • Intense competition
  • Changing regulatory landscape
  • Product liability risks
  • Economic downturns impacting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • MDT
  • BSX
  • ABT
  • SYK

Competitive Landscape

Biomotion Sciences faces competition from large, established medical device companies with significant resources and market share. Its ability to compete depends on its technology, innovation, and ability to secure regulatory approvals and commercialize its products effectively.

Growth Trajectory and Initiatives

Historical Growth: Not available.

Future Projections: Future growth prospects for Biomotion Sciences are unknown without detailed product and financial information. Growth is dependent on successful product development, regulatory approvals, and market adoption.

Recent Initiatives: Information on recent strategic initiatives is not available.

Summary

Biomotion Sciences, represented by its warrant, is a small medical device company facing significant competition. Its success hinges on the development and commercialization of innovative technologies. Regulatory hurdles and financial constraints are key challenges. A strong competitive landscape needs to be considered when accessing the company.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (if available)
  • Industry reports
  • Market research

Disclaimers:

This analysis is based on limited information and general industry knowledge. It should not be considered investment advice. The warrant's value is speculative and subject to market conditions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biomotion Sciences Warrant

Exchange NASDAQ
Headquaters -
IPO Launch date 2024-08-16
Chairman & CEO Mr. Ilan Hadar M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 11
Full time employees 11

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.